Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2002-10-11
2010-10-19
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100
Reexamination Certificate
active
07816335
ABSTRACT:
Therapeutic agents and methods useful to modulate the activity of V3.
REFERENCES:
patent: 5180808 (1993-01-01), Ruoslahti
patent: 5635370 (1997-06-01), Hockfield et al.
patent: WO-91/08230 (1991-06-01), None
patent: WO-00/68361 (2000-11-01), None
patent: WO-0179284 (2001-10-01), None
Anderson, WF. Human Gene Therapy. Nature, 1998 vol. 392 (6679 Suppl):25-30.
Anderson, WF. The Current Status of Clinical Gene Therapy. Human Gene Therapy, 2002 vol. 13:1261-1262.
Crystal, R. Transfer of Genes to Humans: Early Lessons and Obstacles to Success. Science, 1995 vol. 270:404-410.
Branch, A. A Good Antisense Molecule is Hard to Find. TIBS, Feb. 1998 vol. 23, pp. 45-50.
Bowie et al., 1990. Science, vol. 247, pp. 1306-1310. Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions.
Nyberg et al. (Molecular Therapy, 2004 vol. 10: No. 6, pp. 976-980) Workshop on Long-term Follow-up of Participants in Human Gene Transfer Research.
The Times Article (Apr. 14, 2009), Mark Henderson, Science Editor. Analysis: Gene therapy has immense potential After almost two decades, gene therapies have recently started to deliver on their promise.
Cleary, E. G., et al., “Chapter 4. Elastic Tissue, Elastin and Elastin Associated Microfibrils”,In Extracellular Matrix, vol. 2, Molecular Components and Interactions, Edited by Wayne D. Comper, Published by Overseas Publishers Association,(1996),95-140.
Dours-Zimmermann, M. T., et al., “A Novel Glycosaminoglycan Attachment Domain Identified in Tow Alternative Splice Variants of Human Versican”,Journal of Biological Chemistry, 269(52), (Dec. 30, 1994),32992-32998.
Lemire, J. M., et al., “Versican/PG-M Isoforms in Vascular Smooth Muscle Cells”,Arteriosclerosis, Thrombosis&Vascular Biology, 19(7), (1999),1630-1639.
Leonardi, R. , et al., “Immunolocalization of CD44 Adhesion Molecules in Human Periradicular Lesions”,Oral Surgery, Oral Medicine, Oral Pathology and Endodontics, 89(4), (2000),480-485.
Merrilees, M. , et al., “Alteration of Smooth Muscle Cell Phenotype Through Retroviral Insertion of the Gene for Versican Variant V3”,Proceedings of the MBSANZ, 3, Pan Pacific Connective Tissue Societies Symposium, Queenstown, NZ, Nov. 1999 (Abstract Only), 1 Page.
Naso, M. F., et al., “Characterization of the complete genomic structure of the human versican gene and functional analysis of its promoter”,Journal of Biological Chemistry, 269(52), (1994),32999-33008.
Paulus, W. , et al., “Differential Expression of Versican Isoforms in Brain Tumors”,Journal of Neuropathology&Experimental Neurology, 55(5), (1996),528-33.
Schmalfeldt, M. , et al., “Brain Derived Versican V2 is a Potent Inhibitor of Axonal Growth”,Journal of Cell Science, 113 (Part 5), (2000),807-816.
Wight, T. N., “Proteoglycans Are Extracellular Matrix (ECM) Molecules That Influence Multiple Events in Atherosclerosis and Restenosis”, (Abstract Only),1 Page.
Wight, T. N., “Proteoglycans in Atherosclerosis and Restenosis”, (Abstract Only),1 Page.
Wight, T. , et al., “The Role of Matrix in In-Stent Restenosis and Restenosis After Balloon Angioplasty”, (Abstract Only) Presented at the 6th International Drug Delivery Meeting, Geneva, Switzerland, Jan. 27, 2000,1 page.
Zako, M. , et al., “Expression of PG-M(V3), an Alternatively Spliced Form of PG-M without a Chondroitin Sulfate Attachment Region in Mouse and Human Tissues”,Journal of Biological Chemistry, 270(8), (Feb. 24, 1995),3914-3918.
Zimmermann, D. R., et al., “Versican is Expressed in the Proliferating Zone in the Epidermis and in Association with the Elastic Network of Dermis”,J. of Cell Biology, vol. 124, No. 5, (Mar. 1994),817-825.
Zako, M. , et al., “Human pgH3 mRNA for proteoglycan PG-M(V3), complete cds.”,EMBL/Gen Bank/DDBJ Database, D32039—Accession Number, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=1008912,(Oct. 5, 1995).
Wight, T. N., “Proteoglycans Are Extracellular Matrix (ECM) Molecules That Influence Multiple Events in Atherosclerosis and Restenosis”,Proceedings, 11th International Vascular Biology Meeting, 32(3), (Sep. 5-9, 2000, Geneva, Switzerland) (Abstract Only),(2000), p. S085.
Wight, T. N., “Proteoglycans in Atherosclerosis and Restenosis”,Atherosclerosis, 151(1), (Abstract Only),(2000), p. 87.
“Australian Application Serial No. 2001253408, Examiner's First Report on Voluntary Request to Amend Patent mailed May 15, 2008”, 6 pgs.
“Australian Application Serial No. 2001253408, Examiner's Second Report on Voluntary Request to Amend Patent mailed Jun. 12, 2008”, 7 pgs.
“Australian Application Serial No. 2001253408, Response filed Mar. 7, 2007 to Examiner's First Report mailed Jun. 23, 2005”, 16 pgs.
“Australian Application Serial No. 2001253408, Response filed Mar. 22, 2007 to Examiner's Second Report mailed Mar. 16, 2007”, 12 pgs.
“Australian Application Serial No. 2001253408, Examiner's First Report mailed Jun. 23, 2005”, 9 pgs.
“Australian Application Serial No. 2001253408, Examiner's Second Report mailed Mar. 16, 2007”, 13 pgs.
“Australian Application Serial No. 2001253408, Response filed Jun. 6, 2008 to Examiner's First Report on Voluntary Request to Amend Patent mailed May 15, 2008”, 11 pgs.
“Canadian Application Serial No. 2,406,192, Response filed May 12, 2009 to Office Action mailed Nov. 12, 2008”, 20 pgs.
“Canadian Application Serial No. 2,406,192,Office Action mailed Nov. 12, 2008”, 3 pgs.
“European Application Serial No. 01926904.2, Examination Report mailed May 12, 2006”, 5 pgs.
“European Application Serial No. 01926904.2, First Examination Report mailed Nov. 15, 2005”, 6 pgs.
“European Application Serial No. 01926904.2, Invitation mailed Oct. 22, 2008”, 2 pgs.
“European Application Serial No. 01926904.2, Response filed Jan. 9, 2008 to Invitation mailed Jun. 9, 2007”, 8 pgs.
“European Application Serial No. 01926904.2, Response filed Mar. 25, 1006 to First Examination Report mailed Nov. 15, 2005”, 5 pgs.
“European Application Serial No. 01926904.2, Response filed Nov. 5, 2008 to Invitation mailed Oct. 22, 2008”, 27 pgs.
“European Application Serial No. 01926904.2, Response filed Nov. 8, 2006 to Examination Report mailed May 12, 2006”, 7 pgs.
“European Application Serial No. 01926904.2, Office Action mailed Mar. 11, 2009”, 3 pgs.
“International Application Serial No. PCT/US01/11940, International Preliminary Examination Report mailed Aug. 7, 2002”, 3 pgs.
“International Application Serial No. PCT/US01/11940, Written Opinion mailed Jun. 14, 2002”, 2 pgs.
Consiglio, A., et al., “In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice”,Nat. Med., 7(3), (Abstract Only), (2001), 1 pg.
Densmore, C. L., et al., “Gene transfer by guanidinium-cholesterol: dioleoylphosphatidyl-ethanolamine liposome-DNA complexes in aerosol”,J. Gene Med., 1(4), (Abstract Only), (1999), 1 pg.
Goerner, M., et al., “Expansion and transduction of noneriched human cord blood cells using HS-5 conditioned medium and FLT3-L”,Hematother. Stem Cell Res., 9(5), (Abstract Only), (2000), 1 pg.
Gregoriadis, G., “DNA vaccines: a role for liposomes”,Curr. Opin. Mol. Ther., 1(1), (1999), 1 pg.
Hoelters, J., et al., “Nonviral genetic modification mediates effective transgene expression and functional RNA interference in human mesenchymal stem cells”,J. Gene. Med., 7(6), (Abstract Only), (2005), 1 pg.
Horowitz, J., et al., “Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications”,Curr. Opi
Merrilees Mervyn
Wight Thomas N.
Gibbs Terra Cotta
McGarry Sean
Schwegman Lundberg & Woessner, P.A.
LandOfFree
Therapeutic compounds and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compounds and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compounds and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4151498